Cancer Research and Treatment

Original Article

Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy: Yong Joo Hong, Hye-Suk Han, Yusook Jeong, Jiwon Jeong, Sung-Nam Lim, Hyung Jin Choi, Hyun-Jung Jeon, Tae-Keun Oh, Sang-Jeon Lee, Ki Hyeong Lee; Cancer Res Treat. 2014;46(3):288-296. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.288

Purpose
Non-metastatic colorectal cancer patients with diabetes have poor overall survival than those without diabetes. However, the effect of hyperglycemia on survival after diagnosis of metastatic colorectal cancer (CRC) has not been assessed. Therefore, we assessed the impact of hyperglycemia on the survival and infection-related adverse events (AEs) in patients with metastatic CRC. Materials and Methods We reviewed the records of 206 patients with newly diagnosed metastatic CRC who were treated with palliative chemotherapy from March 2000 to December 2012 at Chungbuk National University Hospital. The mean glucose level of each patient was calculated using all available glucose results. Results The mean glucose levels ranged between 76.8 and 303.5 mg/dL, and patients were categorized into quartiles in accordance to their mean glucose level: group 1 (< 106.7 mg/dL), group 2 (106.7-117.2 mg/dL), group 3 (117.3-142.6 mg/dL), and group 4 (> 142.6 mg/dL). The median overall survival for patients in groups 1, 2, 3, and 4 were 22.6, 20.1, 18.9, and 17.9 months, respectively; however, this difference was not statistically significant (p=0.643). Compared with patients in group 1, those in groups 2, 3, and 4 were at a higher risk of infection-related AEs, according to a multivariate analysis (p=0.002). Conclusion Hyperglycemia was not associated with shorter survival; however, it was associated with infection-related AEs in patients with newly diagnosed metastatic CRC receiving palliative chemotherapy.

Citations

Citations to this article as recorded by

Glucocorticoid-Induced Hyperglycemia in Oncologic Outpatients: A Narrative Review Using the Quadruple Aim Framework
Ihab Kandil, Erin Keely
Canadian Journal of Diabetes.2022; 46(7): 730. CrossRef
Association of Comorbid Diabetes With Clinical Outcomes and Healthcare Utilization in Colorectal Cancer Survivors
Susan Storey, Zuoyi Zhang, Xiao Luo, Diane Von Ah, Megan Metzger, Jie Zhang, Amrutha Jakka, Kun Huang
Oncology Nursing Forum.2021; 48(2): 195. CrossRef
The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression
Helga Schultz, Ulrik Pedersen-Bjergaard, Andreas Kryger Jensen, Svend Aage Engelholm, Peter Lommer Kristensen
Clinical and Translational Radiation Oncology.2018; 11: 19. CrossRef
Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities
Susan Storey, Diane Ah, Marilyn Hammer
Oncology Nursing Forum.2017; 44(4): E141. CrossRef
Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors
Roy E. Strowd, Mackenzie C. Cervenka, Bobbie J. Henry, Eric H. Kossoff, Adam L. Hartman, Jaishri O. Blakeley
Neuro-Oncology Practice.2015; 2(3): 127. CrossRef
The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors
Roy E. Strowd, Stuart A. Grossman
Current Treatment Options in Oncology.2015;[Epub] CrossRef

12,267 View
72 Download
7 Web of Science
6 Crossref

First
Prev
Page of 1
Next
Last

Search